Illinois Courts Dismiss Wave of THC Vape Product Class Actions | Cannabis Law Report | How to buy Skittles Moonrock online

Learn how to buy cannabis online. TOP QUALITY GRADE A++

Cannabyss Inc. is the best place online to buy top quality weed, cannabis, vape, marijuana and CBD products. Get your borderless orders delivered at the pickup spot with ease. Top Grade products for client satisfaction.

👉 Click here to Visit our shop! 🛒

7 April 2026

A recent wave of putative class actions accusing Illinois cannabis companies of intentionally miscategorizing vape products has largely collapsed at the pleading stage. Both Illinois federal district courts and state chancery courts have summarily dismissed these cases, finding that the alleged miscategorization does not give rise to a cause of action. In doing so, courts have questioned the fundamental plausibility of these claims. Most recently, an Illinois federal court concluded that the plaintiffs’ claims “are based on the implicit allegation that Illinois cannabis regulators are incompetent on an elementary level that is simply not plausible.” Similarly, in another closely related case, the same court cautioned plaintiffs to “heed the strong and universal concerns about the plausibility of their legal theories that have been expressed by this bench,” noting that “four judges have now dismissed the complaint as implausibly pled.”

I. Illinois Cannabis Regulation and Tax Act

At the center of these cases is a distinction under the Illinois Cannabis Regulation and Tax Act (“CRTA”) between two categories of cannabis products: cannabis concentrates and cannabis-infused products (“CIPs”). Under the CRTA, cannabis concentrates are products “intended to be smoked” (a term defined as the “inhalation of smoke caused by the combustion of cannabis”), while CIPs are products “not intended to be smoked.” The key distinctions between the two categories are twofold: Illinois residents may possess up to 5 grams of cannabis concentrate but only 500 milligrams of THC in a CIP, and the maximum per-package THC limit for a CIP is 100 milligrams, with no per-package limit for concentrates.

Critically, the classification of a cannabis product as a concentrate or a CIP is determined through Illinois’s regulatory approval process. Cannabis products sold in licensed dispensaries are manufactured by licensed cultivators and processors, submitted for regulatory review, and approved by Illinois regulators before reaching consumers. In many of the now-dismissed cases, plaintiffs’ theories necessarily assumed that Illinois cannabis regulators failed to catch what would have been an obvious misclassification–which is an assumption that courts have found to be “simply not plausible”.

Vape products, i.e., products used to inhale vaporized cannabis oil, are commonly sold in Illinois dispensaries in quantities exceeding 500 milligrams of THC. Consumers of these vape products filed over two dozen putative class actions against dozens of Illinois cannabis companies, alleging that such vape products are unlawful because vaping does not involve the inhalation of smoke caused by combustion and therefore exceed the possession and per-package limits for CIPs under the CRTA. The complaints typically contained counts for violations of the Uniform Deceptive Trade Practices Act and the Illinois Consumer Fraud and Deceptive Business Practices Act (“ICFA”), common law fraud, common law fraudulent inducement, breach of express warranty, breach of implied warranty, and unjust enrichment.

II. Why Alleged Noncompliance Hasn’t Translated into Damages

Perhaps the most important and consistent thread running through these decisions is the failure to plead actual damages. Under Illinois law, a private plaintiff asserting claims under the ICFA must allege actual pecuniary loss.

Across these decisions, courts have coalesced around a clear and consistent principle: plaintiffs must allege a concrete, non‑speculative economic injury tied to the actual value of the product received. Allegations that a product was “illegal,” “non‑compliant,” or something the plaintiff would not have purchased if fully informed do not, standing alone, establish recoverable damages under Illinois consumer protection law. Courts have repeatedly rejected attempts to label products as “worthless” based solely on alleged regulatory violations, particularly where plaintiffs do not allege that they failed to receive the benefit of their bargain, paid a price premium, experienced any adverse effects, or received a product different from what was advertised in any functional sense.

Recent decisions have put a fine point on the implausibility of plaintiffs’ damages theories. In rejecting these claims, courts have noted that defendants “did not misrepresent the content or intended use of their products” and that “any person could determine whether Defendants’ intended use complied with the regulations by … ‘simply reading the statute,’ or the product labels.” Other opinions have dismissed assertions that the products were “worthless” as entirely conclusory, pointing out that “[p]laintiff was told he was buying 1,000 milligrams of Vapable Oil containing cannabis, and that is what he got.” Simply put, Illinois courts make clear that damages allegations fail where they are conclusory and where it remains entirely unclear how a plaintiff was deprived of the benefit of their bargain.

Relatedly, courts have been skeptical of generalized “overpayment” theories untethered from any concrete misrepresentation about the product’s ingredients, performance, or objective characteristics. Where complaints rely on the notion that the same product would be worth less if classified differently under the regulatory scheme, courts have characterized those assertions as inherently subjective and insufficient to plead actual pecuniary loss. Without factual allegations connecting the alleged labeling defect to a measurable diminution in value, these claims have consistently failed at the pleading stage.

Notably, courts have also pointed out that the illegality argument cuts against plaintiffs in another way: because cannabis remains a Schedule I controlled substance under federal law, the plaintiffs had already “accepted the risk of purchasing something illegal under federal law,” making it difficult to claim that any additional potential state law noncompliance separately damaged them. That conclusion is reinforced by the undisputed warnings on the product labels, which often warn that “[p]ossession or use of this product may carry significant legal penalties in some jurisdictions and under federal law,” leading courts to find it “patently implausible Plaintiff’s claims that he was somehow duped into engaging in potentially illegal conduct.”

III. Consumers Are Charged with Knowledge of the Law

A second critical basis for dismissal across these cases has been the courts’ rejection of the fraud claims on the grounds that the alleged misrepresentation was one of law, not fact. This distinction is fundamental under Illinois law as misrepresentations or mistakes of law cannot form the basis of a claim for fraud, because “all persons are presumed to know the law.” Courts have found that the core question — whether a Vapable Oil is a cannabis concentrate or a CIP — is a question of statutory interpretation, not a factual misrepresentation. The CRTA provisions defining these two product categories are publicly available to anyone. Because the governing definitions are publicly available, courts have emphasized that consumers are charged with knowledge of the law and cannot premise fraud claims on a defendant’s alleged misapplication of a regulatory framework that plaintiffs themselves could have evaluated. Whether vaping involves “combustion” (and therefore constitutes “smoking” under the CRTA) is a question that requires “one to parse both statutory and dictionary definitions”— a legal exercise, not a factual discovery.

Courts have likewise rejected arguments that manufacturers’ internal intent regarding how a product is meant to be used converts the issue into one uniquely within defendants’ control. Where complaints themselves acknowledge that the products are designed for vaporization rather than combustion, courts have found no missing factual disclosure that could support a fraud theory.

Recent decisions have highlighted the logical impossibility of plaintiffs’ position, questioning how “Illinois regulators dropped the ball in such a blatant way as [plaintiffs’] allegations imply.” Courts have answered that “[t]he likely answer to this question is that … Illinois cannabis regulators understand that ‘vaping’ is a form of ‘smoking,’” and that “if ‘vaping’ is a form of ‘smoking,’ then Defendants’ vapable oil products can be categorized and marketed as ‘concentrates’ without violating Illinois regulations.” Other rulings have similarly emphasized the impracticality of expecting product distributors to resolve unsettled questions of statutory interpretation, observing wryly that “[p]roduct distributors are not expected to have read Justice Scalia’s Reading Law: the Interpretation of Legal Texts, and this is presumably why Illinois courts do not punish retailers who make mistakes in statutory interpretation.” Attempts to frame statutory interpretation as a hidden factual question have therefore failed, particularly where product labels accurately disclose the nature, quantity, and basic characteristics of the product sold. In short, absent a false statement about what the product is or does, courts have declined to allow consumer fraud claims to proceed based on disagreements over legal classification.

IV. What the Decisions Mean for Illinois Cannabis Companies

For Illinois cannabis companies, the sheer volume and consistency of these dismissals provide meaningful relief. That said, licensees should not mistake a string of decisions to rest easy on their regulatory obligations. The dismissals in these cases turned on the plaintiffs’ failure to plead cognizable damages and their attempt to recast a legal classification question as a factual misrepresentation. Notably, existing regulatory guidance already reflects some ambiguity on this issue: the Illinois Department of Agriculture has issued a compliance notice suggesting that oil vape cartridges “can be considered ‘cannabis-infused products’ under the CRTA since vaping would not generally be considered ‘smoking,’ so long as combustion is not required,” while the Illinois Department of Revenue’s implementing regulations define “smoking” more broadly to include “changing cannabis from hard, soft, or liquid form by combustion, heat, electricity, or batteries into a form that can be inhaled by the user.” However, the Illinois Department of Agriculture has proposed regulations specifically categorizing vape products as cannabis concentrate and not cannabis-infused products, which will harmonize the agencies’ categories. Cannabis licensees should monitor any rulemaking developments closely and continue to work with counsel to audit their product classification decisions and labeling practices.

[[View source.]

Source: https://www.jdsupra.com/legalnews/illinois-courts-dismiss-wave-of-thc-3462139/